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Abstract 
BACKGROUND: Minimizing the number of therapy failures and decreasing the diabetic complications can be 
achieved by the application of personalising diabetes therapy, based on patient`s genetics, however, currently, 
personalised Medicine (PM) in diabetes mellitus management is not extensively applied.  
AIM: To assess the knowledge, attitudes, and willingness of physicians in practising of PM in diabetes 
management. 
METHODS: A cross-sectional analytical study was implemented among 126 physicians from six different 
governmental hospitals and 12 primary care centres selected by the stratified random sampling technique in the 
Tabuk region of Saudi Arabia. A structured self-administered questionnaire was utilised for data collection. A 
simple scoring system (scale of 5 points) was utilised to assess knowledge and willingness. Likert scale was 
applied to evaluate the attitudes towards practising PM in DM management by the fixed choice response formats.  
RESULTS: The majority of the participants (97.62%) claimed not receiving any PM and/or genomic medicine 
training. Most of them (82.54%) expressed unsatisfactory knowledge concerning personalised DM, whereas the 
medium level of attitudes was reported among 57.14% of them and a good level of willingness had been observed 
among 76.98% of the physicians. 
CONCLUSION: Emphasizing on essential personalised DM management knowledge aspects should be given a 
considerable priority. Fortunately, positive attitudes and goodwill of physicians towards PM are encouraging and 
should be supported by policymakers. 
 
 
 
 
 
 
Introduction 
 
Diabetes mellitus (DM) is considered one of 
the biggest worldwide health problems of the 21
st 
century as well as it is a considerable contributor to 
the morbidity and mortality all over the world caused 
by the non-communicable diseases. Currently, there 
are 415 million adults living with diabetes mellitus in 
different areas of the world, and this is expected to 
increase by more than 50% over the coming 20 years. 
In addition to that number, there are 318 million adults 
with impaired glucose tolerance, which at higher risk 
of developing diabetes in the future [1], [2]. Saudi 
Arabia has one of the highest diabetic prevalence 
(14.4%) country in the world [3]. Also, Saudi Arabia 
has one of the highest annual incidence rates of type 
1 diabetes in children aged 0-14 years, with 31.4 new 
cases per 100,000 population [4].
 
Despite the 
availability of many effective oral therapies to treat 
diabetes, a considerable percentage of patients do not 
achieve the required glucose-control rate or may be 
subjected to adverse effects, from these drugs [5]. 
Therefore, it is suggested that the response of 
patients to anti-diabetic therapies is subjected to inter-
individual variability, possibly due to genetic factors 
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regarding drug absorption, distribution, and 
metabolism. Therefore, exploring genetic markers 
associated with drug reaction can assist physicians 
with the decisions of drug selection, dose 
modification, therapy duration, and escaping adverse 
drug effects [6].
 
Most of type 2 diabetic patients have 
polygenetic forms of the disease in which each gene 
locus shares only a little risk [7]. For example, the 
association of the E23K variant in KCNJ11 with an 
increased risk for secondary failure of sulfonylurea in 
type 2 DM patients explains how a gene can influence 
the response to a drug [8]. Also, patients with OCT1 
polymorphisms (organic cation transporter 1), which is 
the main port of entry for metformin into hepatocytes 
and enterocytes have a decreased response to 
metformin [9]. Fortunately, nowadays, there are many 
treatment options for diabetes patients that can 
improve outcomes for many of them. However, there 
is still a need to define the appropriate treatment for 
each, since a good number of monotherapy 
treatments fail within three years and diabetes related-
complication and death continue [10], [11].
 
Therefore, 
personalising diabetes therapy based on the genetics 
of patients can reduce the number of treatment 
failures and decreasing the diabetes-associated 
complications but, there is a limited implementation of 
personalised medicine (PM) in treatment of DM [12]. 
Personalised medicine (PM) involves 
identifying specific information about a specific patient 
and then prescribing a drug that is particular for that 
patient [13]. The National Academy of Sciences (NAS) 
defined PM as “the use of genomic, epigenomic, 
exposure and other data to define individual patterns 
of disease, potentially leading to better individual 
treatment” [14].
 
Its goal is to utilise specific information 
about the patient to specify the appropriate 
intervention [15].
 
The intervention could range from a 
common drug given to several patients to a drug 
specific for the patient’s genetic profile [16].
 
Evidence-
based support exists for benefits of applying PM for 
diabetes management in patients with certain 
monogenic forms of diabetes, and it is expected that 
applying this strategy for the more common forms of 
DM will occur with expanding knowledge of polygenic 
determinants of diabetes [17].
 
The application of PM in the clinical practice is 
expected to occur. However, physicians need to be 
aware of the correct test at the correct time and 
interpret the test result in the right way and alter their 
prescription behaviour accordingly. However, we are 
at an early stage of its application, and a dramatic 
shift will be needed in the main fields of medical 
research for this new area of medicine to be fully 
implemented [18].
 
Also, numerous challenges in 
health research exits as there is a need for more 
understand of the diseases 'mechanisms and 
translate research results into practice [19]. 
The study aimed to assess knowledge, 
attitudes, and willingness of physicians to practice PM 
in diabetes mellitus management in Tabuk, Saudi 
Arabia. 
 
 
Material and Methods 
 
A cross-sectional analytical design has been 
adopted in this study, which has been conducted in 
six different governmental hospitals and 12 primary 
care centres in Tabuk province. The province has an 
area of 108,000 km² and a population of 791,535 in 
2015
 
[20]; its capital is Tabuk city and composed of six 
sub-directorates (Tabuk city, Taimaa, Haqel, Duba, 
Alwajh and Umlujj). 
All physicians specialised in internal medicine 
and/or its diabetic related sub-specialities, namely, 
endocrinology, paediatrics, community medicine and 
geriatrics, were included. Physicians who are not 
providing direct patient care, e.g. administrators and 
not practising clinical medicine or diabetic related sub-
specialities were excluded. 
The researchers have followed 3 steps to 
develop a standardised self-administered 
questionnaire: The first step was a literature survey of 
relevant PM studies to identify the pertinent variables 
and formulating a preliminary questionnaire by the 
researchers. The second step was taken the opinion 
of 4 family medicine, and 2 research methodology 
professors and consultants on the proposed 
questionnaire in which the nominal group technique 
has been utilised and then modifications and 
adjustments have been done. The third step was 
testing the validity and reliability of the approved 
questions by the studied experts. Therefore, the 
studied physicians were asked to respond to a 
structured 35-items self-administrated questionnaire, 
designed to evaluate the diabetes management 
practice variables as related to PM. The independent 
variables including age, gender, health facility, highest 
qualification, source of PM awareness, duration of 
work experience in years and training in PM and/or 
genomic medicine and dependent variables 
(knowledge, attitudes and willingness) were selected 
and revised by five medical research experts. 
Approximately 20 minutes were needed by the 
participants to complete it. Ten Knowledge questions 
with correct or incorrect responses were applied. 
Assessment of attitude has been based on the Likert 
scaling method [21] using 10 statements scored as 
follows: 3 for agreement, 2 for undecided and 1 for 
disagreement. The total score has been computed by 
summing the individual scores. Forced-choice 
response scale (yes or no) was applied to assess 
willingness degree.  
Multi-stage random sampling technique was 
applied to allocate the physicians. At the first stage, 
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three sub-directorates from Tabuk province (Tabuk 
city, Taimaa, and Haqel) have been randomly 
selected by simple random sampling technique. At the 
second stage, two governmental hospitals and four 
primary health care centres were selected by the 
stratified random sampling technique from each sub-
directorate. At the third stage, physicians have been 
selected by systematic random sampling technique. 
Only, the eligible subjects have been recruited (126 
physicians). 
Pre-test study has been conducted 
throughout the first two months in the preparatory 
phase of the study to: formulate the research problem 
for more precise investigation, refine the study 
variables, and test the validity and reliability of the 
study tools and instruments. 
Ethical approval for carrying out the study was 
obtained from the regional research committee of 
Tabuk region. Furthermore, all of the study 
participants were briefly informed that all their 
personal information would be kept confidential. 
Refusal to answer any question or withdraw from the 
study at any time was granted to all participants. They 
were informed that there was no “correct” or 
“incorrect” answer, and they were requested to 
express their opinions and beliefs freely. Their 
informed consents were taken. 
Data entry and analysis were done using the 
Statistical Package for Social Sciences version 22 
(SPSS Inc., Chicago, IL). Arithmetic means and 
standard deviations were applied to describe 
continuous data, whereas frequency and percentages 
were applied for categorical data. Chi-squared tests 
were utilised to assess the associations between 
categorical data and unpaired t-test to test for the 
significant difference between two continuous 
variables. A p-value of less than 0.05 was considered 
for statistical significance. 
 
 
Results 
 
The study included 148 physicians, with a 
response rate of 85.06%. Physicians who were not in 
direct contact with patients (n = 6) and/or not 
practising diabetic management (n = 16) were 
excluded. Thus, a total of 126 physicians participated 
in the study. Of the participants, 53.17% and 46.83% 
were males and females, respectively, as shown in 
Table (1) with average age and experience years of 
37 ± 3.68 and 13 ± 6.42, respectively. Only 9.52% of 
them have obtained a doctorate or Saudi Board 
degrees, and surprisingly, 2.38% of them received PM 
and/or Genomic training. The main source of their PM 
knowledge (57.14%) was the internet. 
 
Table 1: General Characteristics of the Studied Physicians 
Character Health Facility Total 
(N = 162) Hospitals 
(N = 28) 
Primary Health 
Care Centers  
(N = 58) 
No. % No. % No. % 
Age (years): Mean± SD 64.92 ± 9..9 69.46 ± 6.28 37.00 ± 3.68 
t = 8.17, P< 0.05 
Sex: 
Males 41 60.29 66 44.83 67 53.17 
Females 27 39.71 62 55.17 59 46.83 
 
2
 = 0.34, P>0.05 
Highest Qualification: 
MBBS 15 22.06 38 65.52 53 42.06 
Diploma 14 20.59 5 8.62 19 15.08 
Master  28 41.17 14 24.14 42 33.34 
Doctorate or Saudi Board 11 16.18 1 1.72 12 9.52 
 
2 
= 26.62, P< 0.05 
Experience years: Mean ± SD 16.16 ± 8.84 9.27 ± 3.57 13 ± 6.42 
t = 5.89, P > 0.05 
PM and/or Genomic Training: 
Received 3 4.41 - 0.00 3 2.38 
Did not receive 65 95.59 58 100.00 123 97.62 
Source of PM Knowledge: 
Internet 39 57.35 33 56.90 72 57.14 
Text books 10 14.71 12 20.69 22 17.46 
Medical journals 11 16.18 4 6.89 15 11.91 
In-service training 5 7.35 7 12.07 12 9.52 
Others 3 4.41 2 3.45 5 3.97 
 
2 
= 0.45, P > 0.05 
 
It’s obvious from Table 2 and Figure 1 that 
only 11.1% of participants have a good level of 
knowledge regarding important PM elements in DM 
management. Also, the fair and poor levels of 
knowledge among them were 6.4% and 82.5%, 
respectively. 
Table 2: Personalized DM Medical Knowledge Assessment of 
the Studied Physicians 
Personalised DM Medical Aspect Studied Physicians’ Knowledge 
(N. 126) 
Correct Answer Incorrect Answer 
No. % No. % 
Definition 7 5.56 119 94.44 
Rationale 10 7.94 116 92.06 
Vision 8 6.35 118 93.65 
Objectives 9 7.14 117 92.86 
Components 9 7.14 117 92.86 
Clinical Diagnostic Methods 26 20.63 100 79.37 
Required laboratory investigations 22 17.46 104 82.54 
Recent PM drugs 16 12.70 110 87.30 
Most important defective genes 7 5.56 119 94.44 
Recent Management Strategies 12 9.52 114 90.48 
Overall Assessment: No. % 
 Good 14 11.1 
 Fair 8 6.4 
 Poor 104 82.5 
 
It’s clear from Table 3 and Figure 2 that nearly 
more than half (57.1%) of participants have positive 
attitudes towards important PM aspects in DM 
management.  
 
Figure 1: Overall Assessment of knowledge of Physicians 
Regarding Personalized Medicine in Diabetes Miletus Management 
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Also, one may notice that 64.29%, 29.37%, 
27.78%, 22.22%, and 19.05% of them have an 
unfavourable attitude towards medical curricula 
sufficiency, widespread applicability, easy patients’ 
accessibility, current achievements and current high 
costs of practising PM in DM management, 
respectively. 
Table 3: Attitudes of the Studied Physicians towards Important 
Personalized DM Medical Aspects 
Personalised DM Medical Aspect Studied Physicians’ Attitudes 
(N. 126) 
Favourable Undecided Unfavourable 
No. % No. % No. % 
Importance in Medical Progress 79 62.70 41 32.54 6 4.76 
Physicians’ Acceptance 102 80.95 20 15.87 4 3.18 
Easy Patients’ Accessibility 42 33.33 49 38.89 35 27.78 
Current Achievements 48 38.10 50 39.68 28 22.22 
Ethical Considerations 82 65.08 27 21.43 17 13.49 
Wide Spread Applicability 38 30.15 51 40.48 37 29.37 
Medical Curricula Sufficiency 9 7.14 36 28.57 81 64.29 
Needed Research 100 79.37 15 11.90 11 8.73 
Current High Costs 73 57.93 29 23.02 24 19.05 
Future Mapping of Medicine 105 83.33 19 15.08 2 1.59 
Overall Attitudes Assessment: No. % 
 Favourable 72 57.1 
 Un-decided 34 27.0 
 Un-favorable 20 15.9 
 
Finally, the results indicate that 77% of 
participants have a good willingness degree regarding 
PM practising in DM management, with 90.48%, 
82.54%, and 80.95% of them reporting that they agree 
to practice PM in DM management, looking for 
training on personalized diabetic management, and 
intersected in personalized diabetic management 
practicing, respectively, Table 4 and Figure 3. 
 
Figure 2: Overall Assessment of Attitudes of Physicians towards 
Personalized Medicine in Diabetes Miletus Management 
 
 
Discussion 
 
Because of the multifactorial and complex 
nature of diabetes mellitus, variability has been 
reported in the response of patients to most currently 
available oral hypoglycemics. Therefore, different 
guidelines recommended using a patient-specific 
approach and choosing management strategies that 
provide the patient with the most benefit and the least 
harm [22]. 
Table 4: Willingness Assessment of the Studied Physicians 
Regarding Personalized DM Medical Practice 
Personalised DM Medical Aspect Studied Physicians’ Willingness 
(N. 126) 
YES NO 
No. % No. % 
Intersected in PM Practicing 102 80.95 24 19.05 
Agree to Practice PM 114 90.48 12 9.52 
Ready to Learn PM Practicing Principles 92 73.02 34 26.98 
Keen to have PM Practicing Degree 90 71.43 36 28.57 
Looking for training on PM 104 82.54 22 17.46 
Will search for recent PM topics-as needed 87 69.05 39 30.95 
Disseminate PM materials on colleagues 71 56.35 55 43.65 
Try to organize PM workshop(s) 48 38.10 78 61.90 
Try to attend PM conference(s) 62 49.21 64 50.79 
Eager to Practice PM 97 76.98 29 23.02 
Overall Enthusiasms’ Assessment: No. % 
Good 97 77.0 
Fair 22 17.4 
Poor 7 5.6 
 
Despite the existence of several studies 
investigating diabetes, there is a lack of evidence 
regarding knowledge, attitudes and practices of 
physicians and their influence on diabetes and its risk 
in the community [23]. 
 
Figure 6: Overall Assessment of Physicians’ Willingness to Practice 
Personalized Medicine in Diabetes Miletus Management 
 
The World Health Organization (WHO) in 
2016 recommended that countries with high diabetic 
prevalence, as the case in Saudi Arabia have to fight 
the rise in diabetes prevalence, to minimise diabetes-
related premature deaths and to improve access to 
main diabetes therapies and basic technologies. Such 
commitment should address the key gaps in the 
diabetes knowledge base and conduct evaluation 
studies of innovative programs intended to change 
attitudes and behaviour [24]. Therefore this study was 
conducted to explore the knowledge, the extent of 
positive attitudes, and willingness of physicians to 
practice PM in diabetes management to provide 
sound and practical data for diabetic decision makers’ 
program development.
 
Personalised treatment of diabetes based on 
patient genomic can reduce the number of therapy 
failures and reducing the rate of diabetic-related 
complications and consequently improve the patients` 
care [12]. However, in the present study, only 2.38% 
of surveyed physicians received PM and/or Genomic 
training. 
 
With many advances in PM on the horizon, 
the researcher has expected that the PM knowledge 
of the studied physicians would be satisfactory and 
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increased exponentially. However, the current results 
showed a considerable very low gap in physicians' 
knowledge regarding the basic principles of 
personalised medicine as only 11.1% of physicians 
had a good knowledge regarding important 
personalised diabetic management elements. Also, 
insufficient knowledge was observed in another study 
carried among oncologists [25]. However, a better 
level of knowledge was reported in another study 
conducted by Chow-White P et al. among oncologists 
[26]. 
The practice of PM for diabetes (PMFD) 
includes 4 processes [27]. First, is the specification of 
genes and biomarkers for diabetes; Second, is the 
allocation of resources to early detect or prevent 
diabetes; Third, is the selection of personalised 
treatments for affected patients; Fourth, is the 
measurement of circulating biomarkers of diabetes to 
evaluate the response to prevention and/or therapy. It 
is important to notice that the detection of efficiency in 
anti-diabetic drug development is possible if 
genetically
 
[28]
 
or nutritionally
 
[29] drug determinants 
are identified in patients with diabetes. Also, patients 
who are at high risk for diabetes, as evidenced by 
genetic testing can be subjected to preventive 
measures, such as alteration in lifestyle or therapies, 
to prevent or at least delay the diabetes development 
[30]. Thus, PM allows prescribing personalised drugs 
with less time lost with an inappropriate response or 
with side effects [31].
 
Unfortunately, in the present 
study, definition, rationale, vision, objectives, 
components, recent drugs, most important defective 
genes and recent management strategies were 
identified correctly by a minority of physicians.  
Despite the lack of knowledge about 
personalised diabetic management reported among 
physicians in the present study, they expressed a 
favourable attitude towards important personalised 
diabetic management aspects as most of them had a 
favourable attitude towards physician`s acceptance. 
However, a considerable proportion of them had a 
favourable concern regarding high cost and ethical 
consideration. The results also indicated good 
willingness degree among physicians regarding 
personalised diabetic management practising, with the 
majority of them reported that they agree to practice 
personalised diabetic management, looking for 
training on personalised diabetic management, and 
intersected in personalised diabetic management 
practising. Recent studies also reported that 
physicians in the USA perceived their lack the 
knowledge and skills to incorporate genomic medicine 
in their practices; despite their positive attitude 
towards it [32], [33]. 
The present study has some important 
limitations. The cross-sectional design was merely 
descriptive without investigating the factors that could 
be associated with physicians` knowledge and 
willingness. Due to the limitations of international 
studies in that area, we could not sufficiently compare 
our findings with others. Also, the results were based 
on a self-administered structured questionnaire (quick, 
easy, participants answer at their convenience, and 
cost-efficient but may lack conscientious responses, 
differences in understanding and interpretation by 
participants and lack of personalisation). Therefore, 
carrying out the study only in Tabuk city could impact 
the generalizability of results. However, the 
transferability model of generalizability [34] can be 
adopted and applied in the Tabuk region and the 
northern parts of Saudi Arabia, given the proximal 
similarity of such geographical and demographic 
parts. Finally, we have to realise that both individual- 
and system-level factors likely contribute to 
differences by race and ethnicity in use and 
responses to PM practice as stressed by Kaphingst, 
and Goodman (2016) [35]. Thus, given the 
demographic and predominant consanguineous 
marriage pattern in KSA, it is of great importance to 
conduct national genomic studies and investigations 
to determine the needed PM areas for the Saudi 
population properly. 
In conclusion, a high priority should be given 
to continuing medical education for physicians 
regarding essential personalised diabetic 
management knowledge. Additionally, discovering the 
positive attitudes and favourable willingness of 
physicians towards the application of PM in patient's 
care are promising and should be encouraged by 
decision makers.‎ 
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